The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations

Virology

Volumn 402, Issue 2, 2010, Pages 228-237

  Wang, J ^a   Liang, H ^a   Bacheler, L ^b   Wu, H ^a   Deriziotis, K ^a   Demeter, L M ^a   Dykes, C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b VircoLab Inc   (United States)

Author keywords

Drug resistance; Drug dependent stimulation of replication; HIV 1; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Replication fitness

Indexed keywords

EFAVIRENZ; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BENZOXAZINES; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77953023743     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.03.018     Document Type: Article

References (45)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59(2):284-291.
2. Archer R.H., Dykes C., Gerondelis P., Lloyd A., Fay P., Reichman R.C., Bambara R.A., Demeter L.M. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 2000, 74(18):8390-8401.
3. Bacheler L.T., Anton E.D., Kudish P., Baker D., Bunville J., Krakowski K., Bolling L., Aujay M., Wang X.V., Ellis D., Becker M.F., Lasut A.L., George H.J., Spalding D.R., Hollis G., Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 2000, 44(9):2475-2484.
4. Bacheler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., Cordova B., Hertogs K., Larder B., Buckery R., Baker D., Gallagher K., Scarnati H., Tritch R., Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. 2001, 75(11):4999-5008.
5. Boyer P.L., Gao H.Q., Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 1998, 42(2):447-452.
6. Chou T.C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 1976, 59(2):253-276.
7. Clark S.A., Shulman N.S., Bosch R.J., Mellors J.W. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. Aids 2006, 20(7):981-984.
8. Collins J.A., Thompson M.G., Paintsil E., Ricketts M., Gedzior J., Alexander L. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 2004, 78(2):603-611.
9. Corbett J.W., Ko S.S., Rodgers J.D., Jeffrey S., Bacheler L.T., Klabe R.M., Diamond S., Lai C.M., Rabel S.R., Saye J.A., Adams S.P., Trainor G.L., Anderson P.S., Erickson-Viitanen S.K. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43(12):2893-2897.
10. Domaoal R.A., Demeter L.M. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int. J. Biochem. Cell Biol. 2004, 36(9):1735-1751.
11. Dykes C., Fox K., Lloyd A., Chiulli M., Morse E., Demeter L.M. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001, 285(2):193-203.
12. Dykes C., Wang J., Jin X., Planelles V., An D.S., Tallo A., Huang Y., Wu H., Demeter L.M. Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J. Clin. Microbiol. 2006, 44(6):1930-1943.
13. Fan J., Gijbels I. Local polynomial modelling and its applications. Monographs on statistics and applied probability 1996, vol. 66. Chapman & Hall, London. 1st ed.
14. Garcia-Lerma J.G., Gerrish P.J., Wright A.C., Qari S.H., Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J. Virol. 2000, 74(20):9339-9346.
15. Gerondelis P., Archer R.H., Palaniappan C., Reichman R.C., Fay P.J., Bambara R.A., Demeter L.M. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J. Virol. 1999, 73(7):5803-5813.
16. Gulick R.M., Ribaudo H.J., Shikuma C.M., Lustgarten S., Squires K.E., Meyer W.A., Acosta E.P., Schackman B.R., Pilcher C.D., Murphy R.L., Maher W.E., Witt M.D., Reichman R.C., Snyder S., Klingman K.L., Kuritzkes D.R. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. 2004, 350(18):1850-1861.
17. Gulick R.M., Ribaudo H.J., Shikuma C.M., Lalama C., Schackman B.R., Meyer W.A., Acosta E.P., Schouten J., Squires K.E., Pilcher C.D., Murphy R.L., Koletar S.L., Carlson M., Reichman R.C., Bastow B., Klingman K.L., Kuritzkes D.R. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006, 296(7):769-781.
18. Harrigan P.R., Bloor S., Larder B.A. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J. Virol. 1998, 72(5):3773-3778.
19. Hu Z., Giguel F., Hatano H., Reid P., Lu J., Kuritzkes D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 2006, 80(14):7020-7027.
20. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 2003, 77(2):1512-1523.
21. Japour A.J., Mayers D.L., Johnson V.A., Kuritzkes D.R., Beckett L.A., Arduino J.M., Lane J., Black R.J., Reichelderfer P.S., D'Aquila R.T., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 1993, 37(5):1095-1101.
22. King O.D., Roth F.P. A non-parametric model for transcription factor binding sites. Nucleic Acids Res. 2003, 31(19):e116.
23. Kleim J.P., Rosner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(1):34-38.
24. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256(5065):1783-1790.
25. Kosalaraksa P., Kavlick M.F., Maroun V., Le R., Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay. J. Virol. 1999, 73(7):5356-5363.
26. Koval C.E., Dykes C., Wang J., Demeter L.M. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N+L100I by the nucleoside resistance mutation L74V. Virology 2006, 353(1):184-192.
27. Llibre J.M., Santos J.R., Puig T., Molto J., Ruiz L., Paredes R., Clotet B. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J. Antimicrob. Chemother. 2008, 62(5):909-913.
28. Lusso P., Cocchi F., Balotta C., Markham P.D., Louie A., Farci P., Pal R., Gallo R.C., Reitz M.S. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J. Virol. 1995, 69(6):3712-3720.
29. Palaniappan C., Fay P.J., Bambara R.A. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem. 1995, 270(9):4861-4869.
30. Perrin V., Mammano F. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants. J. Virol. 2003, 77(18):10172-10175.
31. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44(4):920-928.
32. Radzio J., Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 2008, 73(2):601-606.
33. Ren J., Stammers D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 2008, 134(1-2):157-170.
34. Ren J., Nichols C.E., Stamp A., Chamberlain P.P., Ferris R., Weaver K.L., Short S.A., Stammers D.K. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. 2006, 273(16):3850-3860.
35. Riddler S.A., Haubrich R., DiRienzo A.G., Peeples L., Powderly W.G., Klingman K.L., Garren K.W., George T., Rooney J.F., Brizz B., Lalloo U.G., Murphy R.L., Swindells S., Havlir D., Mellors J.W. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 2008, 358(20):2095-2106.
36. Robbins G.K., De Gruttola V., Shafer R.W., Smeaton L.M., Snyder S.W., Pettinelli C., Dube M.P., Fischl M.A., Pollard R.B., Delapenha R., Gedeon L., van der Horst C., Murphy R.L., Becker M.I., D'Aquila R.T., Vella S., Merigan T.C., Hirsch M.S. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 2003, 349(24):2293-2303.
37. Shulman N.S., Bosch R.J., Mellors J.W., Albrecht M.A., Katzenstein D.A. Genetic correlates of efavirenz hypersusceptibility. Aids 2004, 18(13):1781-1785.
38. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267(5200):988-993.
39. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 1999, 341(25):1865-1873.
40. Sugiura W., Matsuda Z., Yokomaku Y., Hertogs K., Larder B., Oishi T., Kano A., Shiino T., Tatsumi M., Matsuda M., Abumi H., Takata N., Shirahata S., Yamada K., Yoshikura H., Nagai Y. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2002, 46(3):708-715.
41. Tachedjian G., Orlova M., Sarafianos S.G., Arnold E., Goff S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(13):7188-7193.
42. Trivedi V., Von Lindern J., Montes-Walters M., Rojo D.R., Shell E.J., Parkin N., O'Brien W.A., Ferguson M.R. Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility. AIDS Res. Hum. Retroviruses 2008, 24(10):1291-1300.
43. Wang J., Dykes C., Domaoal R.A., Koval C.E., Bambara R.A., Demeter L.M. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 2006, 348(2):462-474.
44. Whitcomb J.M., Huang W., Limoli K., Paxinos E., Wrin T., Skowron G., Deeks S.G., Bates M., Hellmann N.S., Petropoulos C.J. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. Aids 2002, 16(15):F41-F47.
45. Wu H., Huang Y., Dykes C., Liu D., Ma J., Perelson A.S., Demeter L.M. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 2006, 80(5):2380-2389.